Table 3. Univariate and multivariate... | American Society of Hematology

Table 3.

Univariate and multivariate analysis of prognostic factors for survival

Factor	Relative risk	χ²value	P value	95% confidence interval
Univariate
Treatment	1.46	7.97	.005	1.12-1.91
PAdriaCEBO vs PMitCEBO
Age, ≤ 70 vs > 70	1.40	6.19	.01	1.07-1.83
Stage, I/II vs III/IV	2.18	29.08	< .001	1.62-2.93
Sex, male vs female	1.16	1.18	.28	0.89-1.51
WHO PS, 0/1 vs 2-4	2.04	26.32	< .0001	1.57-2.67
Extranodal sites, 0/1 vs > 1	1.14	0.39	.53	0.75-1.73
Multivariate
Treatment	1.58	10.87	.001	1.21-2.06
PMitCEBO vs PAdriaCEBO
Age, ≤ 70 vs > 70	1.45	7.15	.008	1.11-1.89
Stage, I/II vs III/IV	2.05	23.60	< .0001	1.51-2.76
Sex, male vs female	1.19	1.72	.19	0.92-1.55
WHO PS, 0/1 vs 2-4	1.85	18.64	< .0001	1.41-2.42
Extranodal sites, 0/1 vs > 1	1.23	0.90	.34	0.80-1.88

Factor	Relative risk	χ²value	P value	95% confidence interval
Univariate
Treatment	1.46	7.97	.005	1.12-1.91
PAdriaCEBO vs PMitCEBO
Age, ≤ 70 vs > 70	1.40	6.19	.01	1.07-1.83
Stage, I/II vs III/IV	2.18	29.08	< .001	1.62-2.93
Sex, male vs female	1.16	1.18	.28	0.89-1.51
WHO PS, 0/1 vs 2-4	2.04	26.32	< .0001	1.57-2.67
Extranodal sites, 0/1 vs > 1	1.14	0.39	.53	0.75-1.73
Multivariate
Treatment	1.58	10.87	.001	1.21-2.06
PMitCEBO vs PAdriaCEBO
Age, ≤ 70 vs > 70	1.45	7.15	.008	1.11-1.89
Stage, I/II vs III/IV	2.05	23.60	< .0001	1.51-2.76
Sex, male vs female	1.19	1.72	.19	0.92-1.55
WHO PS, 0/1 vs 2-4	1.85	18.64	< .0001	1.41-2.42
Extranodal sites, 0/1 vs > 1	1.23	0.90	.34	0.80-1.88

For abbreviations, see Table 1.